Investigative and Clinical Urology

The Korean Urological Association (대한비뇨의학회)
권호 표지

Expression of Osteopontin and Clusterin in Transitional Cell Carcinoma of the Bladder: Comparison to the Pathologic Stage

방광 이행상피세포암의 병리학적 병기에 따른 Osteopontin과 Clusterin 단백의 발현

Yoon, Jong-Hyun;Lee, Ju-Han;Yeom, Bum-Woo;Won, Nam-Hee;Yoon, Duck-Ki
윤종현;이주한;염범우;원남희;윤덕기

  • Published : 20050400
⟨ Previous Next ⟩

Abstract

Purpose: This study was performed to evaluate the expressions of osteopontin (OPN) and clusterin in a transitional cell carcinoma (TCC) of the urinary bladder, and then compare their expression rates with the tumor invasiveness. Materials and Methods: Twenty-five superficial and 25 invasive TCC were used for immunohistochemical staining. Results: All 25 non-invasive TCC showed a strong positive reaction for OPN. Twenty of the invasive TCC showed a strong positive reaction for OPN, but 5 showed only a weak positive reaction. OPN expression was significantly decreased in the invasive TCC (p=0.02). Eighteen superficial TCC showed a weak positive reaction for clusterin, with 7 showing a negative reaction. Nine invasive TCC showed a strong positive reaction for clusterin, and 11 showed only a weak positive reaction. Five invasive TCC showed a negative reaction for clusterin. Clusterin expression was significantly increased in the invasive TCC (p=0.001). Conclusions: These results may suggest that OPN and clusterin could be used as markers to predict the biological behavior of a TCC.

Keywords

References

  1. Senger DR, Ledbetter SR, Claffey KP, Papadopou]os-Sergiou A, Perruzzi CA, Detmar M. Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the ${\alpha}$ ${\beta}$ integrin, osteopontin, and thrombin. Am J Pathol 1996;149:293-305
  2. Xuan JW, Hota C, Shigeyama Y, D'Errico JA, Somerman MJ, Chambers AF. Site-directed mutagenesis of the arginin-g]ycine-aspartic acid sequence in osteopontin destroys cell adhesion and migration functions. J Cell Biochem 1995;57: 680-90 https://doi.org/10.1002/jcb.240570413
  3. Tuck AB, Chambers AF. The role of osteopontin in breast cancer: clinical and experimental studies. J Mammary Gland BioI Neoplasia 2001;6:419-429 https://doi.org/10.1023/A:1014734930781
  4. Furger KA, Menon RK, Tuckl AB, Bramwell VH, Chambers AF. The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med 2001;1:621-32 https://doi.org/10.2174/1566524013363339
  5. Senger DR, Perruzzi CA. Secreted phosphoprotein markers for neoplastic transformation of human epithelial and fibroblastic cells. Cancer Res 1985;45:5818-23
  6. Chambers AF, Wilson SM, Kerkvliet N, O'Malley FP, Harris JF, Casson AG. Osteopontin expression in lung cancer. Lung Cancer 1996;15:311-23 https://doi.org/10.1016/0169-5002(95)00595-1
  7. Thalmann GN, Sikes RA, Devoll RE, Kiefer JA, Markwalder R, Klima I, et al. Osteopontin: possible role in prostate cancer progression. Clin Cancer Res 1999;5:2271-7
  8. ylvester SR, Morales C, Oko R, Griswold MD. Localization of sulfated glycoprotein-2 (clusterin) on spermatozoa and in the reproductive tract of the male rat. Bioi Reprod 1991;45: 195-207 https://doi.org/10.1095/biolreprod45.1.195
  9. Sodek J, Ganss B, McKee MD. Osteopontin. Crit Rev Oral Bioi Med 2000;11:279-303 https://doi.org/10.1177/10454411000110030101
  10. Shijubo N, Uede T, Kon S, Nagata M, Abe S. Vascular endothelial growth factor and osteopontin in tumor biology. Crit Rev Oncog 2000; 11:135-46
  11. Brakora KA, Lee H, Yusuf R, Sullivan L, Harris A, Colella T, et al. Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer. Gynecol Oncol 2004;93:361-5 https://doi.org/10.1016/j.ygyno.2004.01.050
  12. Koopmann J, Fedarko NS, Jain A, Maitra A, Iacobuzio-Donahue C, Rahman A, et al. Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2004;13:487-91
  13. Brown LF, Papadopoulos-Sergiou A, Berse B, Manseau EJ, Tognazzi K, Perruzzi CA, et al. Osteopontin expression and distribution in human carcinomas. Am J Pathol 1994;145: 610-23
  14. Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF, et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 2004; 10: 184-90 https://doi.org/10.1158/1078-0432.CCR-1405-2
  15. Terashi T, Aishima S, Taguchi K, Asayama Y, Sugimachi K, Matsuura S, et al. Decreased expression of osteopontin is related to tumor aggressiveness and clinical outcome of intrahepatic cholangiocarcinoma. Liver Int 2004;24:38-45 https://doi.org/10.1111/j.1478-3231.2004.00886.x
  16. Crawford HC, Matrisian LM, Liaw L. Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Res 1998;58:5206-15
  17. Slawin K, Sawczuk IS, Olsson CA, Buttyan R. Chromosomal assignment of the human homologue encoding SGP-2. Biochern Biophys Res Commun 1990;172:160-4 https://doi.org/10.1016/S0006-291X(05)80187-1
  18. Lakins J, Bennett SA, Chen JH, Arnold JM, Morrissey C, Wong P, et al. Clusterin biogenesis is altered during apoptosis in the regressing rat ventral prostate. J Bioi Chem 1998;273: 27887-95 https://doi.org/10.1074/jbc.273.43.27887
  19. Ahuja HS, Tenniswood M, Lockshin R, Zakeri ZF. Expression of clusterin in cell differentiation and cell death. Biochem Cell Bioi 1994;72:523-30 https://doi.org/10.1139/o94-070
  20. Rittmaster RS, Magor KE, Manning AP, Norman RW, Lazier CB. Differential effect of 5 alpha-reductase inhibition and castration on androgen-regulated gene expression in rat prostate. Mol Endocrinol 1991;5:1023-9 https://doi.org/10.1210/mend-5-7-1023
  21. Nickerson T, Pollak M, Huynh H. Castration-induced apoptosis in the rat ventral prostate is associated with increased expression of genes encoding insulin-like growth factor binding proteins 2,3,4 and 5. Endocrinology 1998;139:807-10 https://doi.org/10.1210/en.139.2.807
  22. Kadomatsu K, Anzano MA, Slayter MV, Winokur TS, Smith JM, Sporn MB. Expression of sulfated glycoprotein 2 is associated with carcinogenesis induced by N-nitroso-N-methylurea in rat prostate and seminal vesicle. Cancer Res 1993;53: 1480-3
  23. Steinberg J, Oyasu R, Lang S, Sintich S, Rademaker A, Lee C, et al. Intracellular levels of SGP-2 (clusterin) correlate with tumor grade in prostate cancer. Clin Cancer Res 1997;3: 1707-11
  24. Redondo M, Villar E, Torres-Munoz J, Tellez T, Morell M, Petito CK. Overexpression of clusterin in human breast carcinoma. Am J Pathol 2000; 157:393-9 https://doi.org/10.1016/S0002-9440(10)64552-X
  25. Zhang LY, Ying WT, Mao YS, He HZ, Liu Y, Wang HX, et al. Loss of clusterin both in serum and tissue correlates with the tumorigenesis of esophageal squamous cell carcinoma via proteomics approaches. World J Gastroenterol 2003;9:650-4 https://doi.org/10.3748/wjg.v9.i4.650
  26. Scaltriti M, Brausi M, Amorosi A, Caporali A, D'Arca D, Astancolle S, et al. Clusterin (SGP-2, ApoJ) expression is downregulated in low- and high-grade human prostate cancer. Int J Cancer 2004;108:23-30 https://doi.org/10.1002/ijc.11496
  27. Miyake H, Gleave M, Kamidono S, Hara I. Overexpression of clusterin in transitional cell carcinoma of the bladder is related to disease progression and recurrence. Urology 2002; 59: 150-4 https://doi.org/10.1016/S0090-4295(01)01484-4